Loading…
Loading…
what would you say are the leading indicators of a rebound in aesthetics, I'm just trying to assess what green shoots perhaps you may be seeing
What would you say are the main elements that you'd want to see in reform
is it fair to say that you think '25 could be the trough or have already seen a trough in terms of the growth rate
you guys called out the partial impairment today in the press release. Just want to get your perspective as to what the drivers are for the remaining value
post ADA, were there any changes that you guys made to Phase III, just thinking increased entry criteria or maybe pace of titration just to optimize discontinuations?
the OUS contribution, I think, is going to be much bigger when you compare to Descovy or Truvada and PrEP
what's the gating factor for selecting the best phase three combo? And related to that, you know, while you haven't seen resistance with len
do you guys view all the different Len treatment options that you detailed on Slide 20 as eventually replacing Biktarvy
is the ultimate goal to have meaningfully more indications than Tirzepatide just given the oral convenience?
Can you guys speak to trends on duration of therapy or maybe real-world safety tolerability
maybe talk about the selection of the indications that you just announced from a mechanism perspective
can you talk about Merck's mitigating strategies as an offset whether it's a new CapEx cycle
is there an inventory threshold that you need to see to start shipping again